These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29560472)

  • 1. Combination antibiotics against
    Kapoor P; Murphy P
    Heliyon; 2018 Mar; 4(3):e00562. PubMed ID: 29560472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 3. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.
    Foweraker JE; Laughton CR; Brown DF; Bilton D
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4809-15. PubMed ID: 19704123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 7. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model.
    Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB
    J Glob Antimicrob Resist; 2021 Sep; 26():55-63. PubMed ID: 34023531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis.
    Lasko MJ; Huse HK; Nicolau DP; Kuti JL
    Ann Clin Microbiol Antimicrob; 2021 Jan; 20(1):9. PubMed ID: 33468149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa Isolates From a Cohort of Mexican Children With Cystic Fibrosis Show Adaptation to a Chronic Phenotype.
    Rosales-Reyes R; Rodríguez-Alvarado M; Lezana-Fernández JL; Sánchez-Lozano JY; Gayosso-Vázquez C; Jarillo-Quijada MD; Toledano-Tableros JE; Arredondo-Mercado MJ; Alcántar-Curiel MD; Lincopan N; Vidal JE; Lascurain R; Valvano MA; Santos-Preciado JI
    Pediatr Infect Dis J; 2020 Oct; 39(10):899-906. PubMed ID: 32453200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
    Bradbury R; Champion A; Reid DW
    Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic and Phenotypic Diversity of Staphylococcus aureus Isolates from Cystic Fibrosis Patient Lung Infections and Their Interactions with Pseudomonas aeruginosa.
    Bernardy EE; Petit RA; Raghuram V; Alexander AM; Read TD; Goldberg JB
    mBio; 2020 Jun; 11(3):. PubMed ID: 32576671
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Moskowitz SM; Foster JM; Emerson J; Burns JL
    J Clin Microbiol; 2004 May; 42(5):1915-22. PubMed ID: 15131149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update.
    Okoliegbe IN; Hijazi K; Cooper K; Ironside C; Gould IM
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.